Insulet Corporation combines best-in-class growth of 34% year-over-year with a perfect four-quarter earnings beat streak and a strong economic moat, but its current technical downtrend and failed momentum gate create a timing headwind that must resolve before the quality-growth combination can be fully valued.
Thesis pillars
- Earnings Beat And Growth↓Deteriorating
- Wide Moat Quality Profile→Stable
- Technical Momentum Recovery↑Improving
- +1 more pillar — see the Why tab for full reasoning
Insulet Corporation (PODD) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $144.03, but acceptable to hold if already in. Reasons: Concentration risk — Product: Omnipod product platform; Concentration risk — Supplier: sole-sourced components.
Insulet Corporation develops and manufactures the Omnipod tubeless insulin delivery platform for people with insulin-dependent diabetes, sold in 25 countries with Omnipod 5 available in 19. Revenue derives almost entirely from Omnipod product sales through three distributors... Read more
Hold if already holding. Not a fresh buy at $144.03, but acceptable to hold if already in. Reasons: Concentration risk — Product: Omnipod product platform; Concentration risk — Supplier: sole-sourced components. Chart setup: Death cross, below all MAs, RSI 34, MACD bearish. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
About Insulet Corporation
About Insulet Corporation
Insulet Corporation's Omnipod 5 Automated Insulin Delivery System—FDA-cleared in 2022 and expanded to type 2 diabetes in August 2024—anchors a platform sold across 25 countries. Three unnamed distributors (Distributor A, B, and C) accounted for 27%, 26%, and 25% of total revenue respectively in 2025, while international sales represented 28% of revenues. During 2025, Insulet launched Omnipod 5 integration with Dexcom's G7 CGM in the iOS app and across Germany, Sweden, Denmark, Finland, and Italy.
Insulet sells Omnipod through U.S. wholesalers and pharmacies covered by commercial insurance, Medicare Part D, and Medicaid via contracts established in all 50 states. Internationally, the company distributes directly to consumers or through intermediaries that establish local reimbursement contracts. Manufacturing spans three sites: Acton, Massachusetts; Johor, Malaysia; and contract lines operated by a third-party manufacturer in China—a geography where supply disruption risk and post-COVID pressure to reduce medical device dependency are both flagged in the 10-K. The company competes with Medtronic Diabetes (being spun out as an independent company), Tandem Diabetes Care, and Beta Bionics in the insulin pump segment, as well as MDI therapy providers. Insulet's non-insulin Drug Delivery product line—generating substantially all revenue from Amgen's Neulasta Onpro kit under an agreement expiring December 2028—faces separate commercialization risks tied to pharmaceutical partner performance.
Show full overview
Sole-sourced component supply poses a material continuity risk. Insulet purchases application-specific integrated circuit chips, Bluetooth low-energy chips, and other specialized parts from suppliers that, in some instances, own the related intellectual property exclusively—leaving the company with no alternate source. These components are critical to product design and functionality, managed only by holding inventory at both Insulet and the supplier. Substantially all U.S. inventory is held at a single Massachusetts location, adding geographic concentration to the component-level supply risk.
See also: Healthcare · Medical Devices
From Insulet Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-16Recent Developments — Insulet Corporation
Latest news
- NEWS PODD DEADLINE: Levi & Korsinsky Reminds Insulet Corporation Investors of Upcoming Securities Class Action Deadline - Mor — Morningstar negative
- NEWS Insulet Corporation (PODD) Q1 2026 Earnings: EPS Surpasses Estimates by 16%, Stock Edges Higher - Guidance Revision Tren — dars.gov.et positive
- NEWS Insulet Corporation (PODD) Q1 2026 Earnings: EPS Surpasses Estimates by 16%, Stock Edges Higher - Revenue Per Share - da — dars.gov.et positive
- NEWS PODD DEADLINE: Levi & Korsinsky Reminds Insulet Corporation Investors of Upcoming Securities Class Action Deadline - PR — PR Newswire negative
- NEWS INSULET CORPORATION INVESTORS WITH LOSSES HAVE UNTIL AUGUST - GlobeNewswire — GlobeNewswire negative
Generated 2026-08-16T16:27:15Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerDistributor A27%10-K Item 1: 'Distributor A| 27%'
- MEDIUMCustomerDistributor B26%10-K Item 1: 'Distributor B| 26%'
- MEDIUMCustomerDistributor C25%10-K Item 1: 'Distributor C| 25%'
- HIGHProductOmnipod product platform10-K Item 1A: 'We expect to continue to derive nearly all our revenue from our Omnipod product platform'
- HIGHSuppliersole-sourced components10-K Item 1: 'we are sole-sourced, with the supplier controlling the intellectual property rights'
- HIGHCustomerAmgen (Drug Delivery)10-K Item 1A: 'Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen's Neulasta Onpro kit'
- MEDIUMGeographicInternational28%10-K Item 1A: 'International sales made up 28% of our revenues in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $144.03, but acceptable to hold if already in. Reasons: Concentration risk — Product: Omnipod product platform; Concentration risk — Supplier: sole-sourced components. Chart setup: Death cross, below all MAs, RSI 34, MACD bearish. Maintain position. Not compelling to add more. Target $154.72 (+7.4%), stop $133.31 (−8.0%), A.R:R 0.7:1. Score 6.1/10, moderate confidence.
Take-profit target: $154.72 (+7.9% upside). Target $154.72 (+7.4%), stop $133.31 (−8.0%), A.R:R 0.7:1. Stop-loss: $133.31.
Concentration risk — Product: Omnipod product platform; Concentration risk — Supplier: sole-sourced components; Thin upside margin: 7.9%.
Insulet Corporation trades at a P/E of 26.9 (forward 18.6). TrendMatrix value score: 5.6/10. Verdict: Hold.
33 analysts cover PODD with a consensus score of 4.2/5. Average price target: $172.
What does Insulet Corporation do?Insulet Corporation develops and manufactures the Omnipod tubeless insulin delivery platform for people with...
Insulet Corporation develops and manufactures the Omnipod tubeless insulin delivery platform for people with insulin-dependent diabetes, sold in 25 countries with Omnipod 5 available in 19. Revenue derives almost entirely from Omnipod product sales through three distributors accounting for roughly 78% of sales combined, with international markets representing 28% of revenues in 2025.